AST-120 + pentoxifylline

AST-120 + pentoxifylline is a combination of two small molecule drugs, each with distinct mechanisms and clinical uses, primarily investigated for their potential synergistic effects in chronic kidney disease (CKD) and related conditions. - **AST-120** is an oral spherical carbon adsorbent developed to delay the progression of CKD by adsorbing uremic toxins in the gastrointestinal tract, thereby reducing their systemic absorption and subsequent renal damage. It has been shown to lower rates of end-stage renal disease and composite renal outcomes when used in tailored dosing regimens[1]. - **Pentoxifylline** is a methylxanthine derivative and nonselective phosphodiesterase inhibitor with anti-inflammatory, antiproliferative, antifibrotic, and hemorheological properties. It improves blood flow by decreasing blood viscosity and inhibiting platelet aggregation. Pentoxifylline also inhibits tumor necrosis factor (TNF) production via increased intracellular cAMP levels[2][3][4]. Clinically approved for intermittent claudication due to peripheral artery disease, it has been repurposed for renoprotection in diabetic kidney disease due to its anti-inflammatory effects[2]. The rationale for combining these agents lies in targeting multiple pathogenic pathways involved in CKD progression—uremic toxin reduction (AST-120) alongside anti-inflammatory/antifibrotic actions (pentoxifylline). However, there are no widely recognized brand names or fixed-dose combination products currently marketed under this dual formulation.

Brand names

KremezinTrental

Other names

AST-120 and pentoxifyllineAST120 and pentoxifyllineAST 120 and pentoxifyllineAST-120 + PTXAST-120 and pentoxyphyllineAST120 and pentoxyphyllineAST 120 and pentoxyphyllineKremezin + pentoxifylline